Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;28(47):2300186.
doi: 10.2807/1560-7917.ES.2023.28.47.2300186.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

Angela Mc Rose  1 , Nathalie Nicolay  2 , Virginia Sandonis Martín  3 , Clara Mazagatos  4   5 , Goranka Petrović  6 , F Annabel Niessen  7 , Ausenda Machado  8 , Odile Launay  9   10   11 , Sarah Denayer  12 , Lucie Seyler  13 , Joaquin Baruch  14 , Cristina Burgui  15   5 , Isabela I Loghin  16   17 , Lisa Domegan  18 , Roberta Vaikutytė  19 , Petr Husa  20   21 , George Panagiotakopoulos  22 , Nassera Aouali  23 , Ralf Dürrwald  24 , Jennifer Howard  1 , Francisco Pozo  3 , Bartolomé Sastre-Palou  25 , Diana Nonković  26 , Mirjam J Knol  7 , Irina Kislaya  8 , Liem Binh Luong Nguyen  10 , Nathalie Bossuyt  12 , Thomas Demuyser  13 , Aušra Džiugytė  14 , Iván Martínez-Baz  15   5 , Corneliu Popescu  27   28 , Róisín Duffy  18 , Monika Kuliešė  19 , Lenka Součková  21 , Stella Michelaki  22 , Marc Simon  29 , Janine Reiche  24 , María Teresa Otero-Barrós  30 , Zvjezdana Lovrić Makarić  6 , Patricia Cjl Bruijning-Verhagen  31   7 , Verónica Gomez  8 , Zineb Lesieur  10 , Cyril Barbezange  12 , Els Van Nedervelde  13 , Maria-Louise Borg  14 , Jesús Castilla  15   5 , Mihaela Lazar  32 , Joan O'Donnell  18 , Indrė Jonikaitė  19 , Regina Demlová  20 , Marina Amerali  22 , Gil Wirtz  23 , Kristin Tolksdorf  24 , Marta Valenciano  1 , Sabrina Bacci  2 , Esther Kissling  1 ; I-MOVE-COVID-19 hospital study team  33 ; VEBIS hospital study team  33 ; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to the named authors)
Collaborators, Affiliations

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

Angela Mc Rose et al. Euro Surveill. 2023 Nov.

Abstract

IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.

Keywords: Alpha; Delta; Europe; SARS-CoV-2; hospital; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Countries and study sites participating in I-MOVE-COVID-19 and VEBIS hospital vaccine effectiveness studies, by provision of data for this analysis, Europe, 2021
Figure 2
Figure 2
Exclusions for I-MOVE-COVID-19 and VEBIS hospital vaccine effectiveness studies, Europe, 2021 (n = 8,616)
Figure 3
Figure 3
Number of SARI patients by case status and week of COVID-19 vaccination (second and booster doses) or swab, I-MOVE-COVID-19 and VEBIS hospital vaccine effectiveness studies, Europe, 2021 (n = 4,736)
See this image and copyright information in PMC

References

    1. Harder T, Koch J, Vygen-Bonnet S, Külper-Schiek W, Pilic A, Reda S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021;26(28):2100563. 10.2807/1560-7917.ES.2021.26.28.2100563 - DOI - PMC - PubMed
    1. European Medicines Agency (EMA). COVID-19 medicines. Amsterdam: EMA. [Accessed: 28 Mar 2021]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-thr...
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. 10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201. 10.1056/NEJMoa2101544 - DOI - PMC - PubMed

LinkOut - more resources